Publications
Featured Publications
Interleukin-18 Engineered For Resistance to IL-18 Binding Protein (IL-18BP) and Half-Life Extension to Enhance Its Therapeutic Potential
American Association for Cancer Research (AACR) Annual Meeting
April 2024
Generation of tumor targeted self-assembling split IL-12p35 and IL-12p40 subunits for the treatment of cancer
American Association for Cancer Research (AACR) Annual Meeting
April 2024
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2022
All Publications
Nemvaleukin Alfa, a Novel Engineered IL-2 Cytokine, in Combination With the Anti-PD-1 Antibody Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (ION-01 Study)
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2021
ARTISTRY-6: Nemvaleukin Alfa Monotherapy in Patients With Advanced Mucosal and Cutaneous Melanoma
Society for Melanoma Research Congress
October 2021
Clinical Development of Nemvaleukin Alfa (ALKS 4230) for Advanced Solid Tumors With High Unmet Need: From Design to Bench to Bedside
Cytokines in Cancer Immunotherapy Workshop
October 2021
Antitumor Efficacy and Immune Profiling of the Mouse Ortholog of Nemvaleukin Alfa, a Novel Engineered IL-2 Fusion Protein, in an Orthotopic Mouse Model of Small Cell Lung Cancer Alone or in Combination with Standard Chemotherapy
European Society for Medical Oncology (ESMO) Congress
September 2021
ARTISTRY-6: Nemvaleukin Alfa Monotherapy in Patients With Advanced Mucosal and Cutaneous Melanoma
European Society for Medical Oncology (ESMO) Congress
September 2021
Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys
The Journal of Pharmacology and Experimental Therapeutics
August 2021
A Phase 2 Clinical Trial of Nemvaleukin Alfa (ALKS 4230) Combined With Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): the ION-01 Trial
American Head & Neck Society (AHNS) International Conference
July 2021
Nemvaleukin Alfa Monotherapy in Patients With Advanced Melanoma: ARTISTRY-1
European Association of Dermato Oncology (EADO) Congress
April 2021
Phase 1/2 Study of Subcutaneously Administered ALKS 4230, a Novel Engineered Cytokine, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors: ARTISTRY-2
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2020
ALKS 4230: A Novel, Engineered Interleukin Variant Immunotherapy – Clinical Data Updates from ARTISTRY-1 Trial
European Society for Medical Oncology Virtual Congress 2020
September 2020
The Combination of a Mouse Ortholog of ALKS 4230, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, and the Angiogenesis Inhibitor Lucitanib Enhances Antitumor Activity
American Association for Cancer Research Annual Meeting
April 2020
Clinical Outcomes of Ovarian Cancer Patients Treated With ALKS 4230, a Novel Engineered Cytokine, in Combination With Pembrolizumab: ARTISTRY-1 Trial
Society for Immunotherapy of Cancer (SITC) Annual Meeting
April 2020